ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Forty one patients experienced a BCR-ABL transcript fluctuation in the qRT-PCR without clear molecular relapse.52 The TWISTER study is a prospective clinical trial which have used very similar as those in a STIM study entry and molecular relapse criteria for 40 chronic phase CML patients who discontinued imatinib.